文献速递慢性肾脏病急性肾损伤血液净化与透析

肾脏健康优化诊疗:基于绩效的激励支付系统(MIPS)价值路径的开发

Optimal Care for Kidney Health: Development of a Merit-based Incentive Payment System (MIPS) Value Pathway.
PubMed 文献 · J Am Soc Nephrol · 2023-07-03

本文介绍美国肾脏病学会质量委员会于2020年5月至2022年7月通过迭代共识流程开发「肾脏健康优化诊疗MIPS价值路径(MVP)」,采用两轮排序选择投票从9项质量指标、43项改进活动和3项成本措施中筛选,最终MVP于2023年Medicare医师费用表最终规则中发布。

要点

  • MIPS是CMS强制实施的绩效付费项目,旨在激励高质量诊疗、促进持续改进、便利信息电子交换并降低医疗成本。
  • 既往研究提示MIPS在评估肾脏病诊疗方面存在行政复杂性、与肾脏病诊疗相关性有限、无法跨肾脏病执业机构比较绩效等局限。
  • 肾脏健康优化诊疗MVP纳入血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂使用、高血压控制、再入院、需要透析的急性肾损伤及预立医疗照护计划相关指标。

核心结论

  • 肾脏病MVP旨在简化MIPS中的指标选择,并作为亚专科专业组织与国家监管机构协作制定政策的案例。

研究设计与样本

  • 美国肾脏病学会质量委员会于2020年5月至2022年7月通过迭代共识构建流程开发肾脏健康优化诊疗MIPS价值路径(MVP)。
  • 采用两轮排序选择投票从9项质量指标、43项改进活动和3项成本措施中筛选纳入MVP的指标。
  • 指标选择与CMS MVP开发团队协作迭代完善,新MIPS指标通过CMS的「考虑中措施」流程提交。

主要发现

  • 肾脏健康优化诊疗MVP于2023年Medicare医师费用表最终规则中发布。
  • MVP包含与血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂使用、高血压控制、再入院、需要透析的急性肾损伤及预立医疗照护计划相关的指标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 既往研究提示MIPS项目在评估肾脏病诊疗方面存在若干局限,包括行政复杂性、与肾脏病诊疗相关性有限以及无法跨肾脏病执业机构比较绩效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Merit-based Incentive Payment System (MIPS) is a mandatory pay-for-performance program through the Centers for Medicare & Medicaid Services (CMS) that aims to incentivize high-quality care, promote continuous improvement, facilitate electronic exchange of information, and lower health care costs. Previous research has highlighted several limitations of the MIPS program in assessing nephrology care delivery, including administrative complexity, limited relevance to nephrology care, and inability to compare performance across nephrology practices, emphasizing the need for a more valid and meaningful quality assessment program. This article details the iterative consensus-building process used by the American Society of Nephrology Quality Committee from May 2020 to July 2022 to develop the Optimal Care for Kidney Health MIPS Value Pathway (MVP). Two rounds of ranked-choice voting among Quality Committee members were used to select among nine quality metrics, 43 improvement activities, and three cost measures considered for inclusion in the MVP. Measure selection was iteratively refined in collaboration with the CMS MVP Development Team, and new MIPS measures were submitted through CMS's Measures Under Consideration process. The Optimal Care for Kidney Health MVP was published in the 2023 Medicare Physician Fee Schedule Final Rule and includes measures related to angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use, hypertension control, readmissions, acute kidney injury requiring dialysis, and advance care planning. The nephrology MVP aims to streamline measure selection in MIPS and serves as a case study of collaborative policymaking between a subspecialty professional organization and national regulatory agencies.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Tummalapalli SL, Struthers SA, White DL, et al. Optimal Care for Kidney Health: Development of a Merit-based Incentive Payment System (MIPS) Value Pathway. J Am Soc Nephrol. 2023. PMID: 37400103. doi:10.1681/ASN.0000000000000163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。